Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

DefiniGEN Closes £2.3M Series A Fundraising

Published: Monday, June 02, 2014
Last Updated: Monday, June 02, 2014
Bookmark and Share
Funding will be used to launch new stem cell products for drug discovery and regenerative medicine.

DefiniGEN Ltd today announced the final closing of its Series A funding round. The latest £1 million ($1.6 million) placement for ordinary shares brings to a close a cumulative total for the round of £2.28 million ($3.83 million), which will support the international expansion of the business and the commercial launch of new products.

The funding round was led by Cambridge Enterprise and 24 Haymarket, with existing investors Dr. Jonathan Milner, CEO, Abcam Plc, Providence Investment Company, and Cambridge Capital Group also participating. New investors include LBA, Wren Capital, and Ranworth Capital.

This latest funding will be used to drive profitable growth across four key areas:
•         expansion of direct commercial presence across Europe, North America and Asia Pacific with dedicated local marketing presence
•         investment in automation at the Company’s enlarged laboratory facility and recruitment of high quality production staff
•         expansion of product line offerings in new areas including human induced pluripotent stem cell (iPSC) derived hepatocyte types, pancreatic beta cells and lung cells, with others to follow
•         strengthening of the Company’s intellectual property portfolio

DefiniGEN is focused on serving the growing need in the pharmaceutical industry for more accurate predictions of efficacy and toxicity in drug candidates ahead of clinical trials. Its platform technology OptiDIFF is a revolutionary stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. These cells can be used as predictive in vitro models to support the development of safer and more effective treatments for diseases. Since its foundation in April 2012 DefiniGEN has undergone rapid growth, generating first sales within six months of seed investment and securing contracts with global pharma companies.

Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN, said: “We are at an exciting inflexion point in the development of human induced pluripotent stem cell technology. The funds raised will allow the rapid development of libraries of human cells customised for genetic and ethnic profiles for drug discovery and regenerative applications. These advances are generating substantial interest from global pharma.”

Marek Gumienny, Lead Investor, 24 Haymarket, and formerly Chairman of Candover Partners Ltd, said: “DefiniGEN is a dynamic innovative company with a business model that can harness the huge potential of stem cell technology. Stem cells have the power to revolutionise healthcare, radically improve the efficiency and economics of drug development and enable personalised regenerative medicine to become a reality.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Robotic Cleaning Technique Could Automate Neuroscience Research
New robotic cleaning technique allows pipettes used in patch-clamping to be re-used up to 11 or more times.
Study Implicates Glial Cells in Fragile X Syndrome
The genetic defect behind a common cause of mental retardation affects not only neurons but also the more numerous glial cells in the brain.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
A Step Forward in Building Functional Human Tissues
Researchers at Wyss Institute have bioprinted a tubular 3D renal architecture that recapitulates functions of the kidney.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos